ORIGINAL RESEARCH article
Front. Med.
Sec. Gastroenterology
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1486963
Clinical Significance of Elevated Tumor Markers in Patients with Biliary Pancreatitis
Provisionally accepted
- Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: This study explores the clinical significance of elevated tumor markers in patients with biliary pancreatitis. It aims to develop a machine learning-based clinical prediction model to facilitate early intervention and improve outcomes in acute biliary pancreatitis (ABP). Method: We collected data from patients admitted with biliary pancreatitis to the Department of General Surgery at Jiangsu University Hospital from January 1, 2016, to December 31, 2023. We recorded general patient information. Result: Markers including Carbohydrate Antigen (CA) 50, CA19-9, CA125, CA724, CA242, ferritin, leukocyte count, high-sensitivity C-reactive protein (HS-CRP), total bilirubin, direct bilirubin, alanine aminotransferase, and aspartate aminotransferase were significantly higher in the severe acute pancreatitis (SAP) and moderately severe acute pancreatitis (MSAP) groups compared to the mild acute pancreatitis (MAP) group (P < 0.05). Univariate logistic regression analysis identified white blood cell count, HS-CRP, CA50, CA19-9, CA125, urinary amylase, total bilirubin, aspartate aminotransferase, and hospitalization duration as risk factors for progression to MSAP or SAP. Multivariate logistic regression analysis confirmed hospitalization duration as an independent risk factor. Conclusion: Elevated tumor markers have clinical significance in biliary pancreatitis. We propose a clinical prediction model based on machine learning to screen variables and guide treatment adjustments for MAP.
Keywords: Elevated, tumor markers, biliary, Pancreatitis, Clinical significance
Received: 14 Nov 2024; Accepted: 13 May 2025.
Copyright: © 2025 Han, Li, Li, Zhang, Chen and Xin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Fan Xin, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.